Why Lilly’s Obesity Pill Miss Shook Investors

Lilly's stock crashed after its obesity pill trial fell short. What went wrong, and what’s next for the weight-loss drug...

07/08/2025

4 views

Eli Lilly’s Q2 2025: Mounjaro, Zepbound Drive Growth

Eli Lilly's Q2 2025 earnings beat expectations with blockbuster drug sales. But what’s next for their obesity pill trials? Click...

07/08/2025

2 views

Will Eli Lilly's Q2 earnings soar with Zepbound's success? Analysts predict big wins, but what about CVS's Wegovy move? Click...

06/08/2025

2 views